1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Boston Scientific Corp.

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, The company advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.
Michael Mahoney

300 Boston Scientific Way
Marlborough, Massachusetts 01752-1291
Phone: 15086834000


Boston Scientific Lifts 2024 Profit Forecast On Strong Growth From Cardiovascular Devices, Stock Soars
Apr 24, 2024 16:42pm

Boston Scientific Corporation (NYSE: BSX ) shares are trading higher on Wednesday after the company reported better-than-expected first-quarter earnings and issued guidance . The company generated first-quarter revenues of $3.86 billion, beating the consensus estimate of $3.69 billion . Sales soared 13.8% year-over-year on a reported basis, 15% on an operational basis, and 13.1% on an organic basis, beating the management guidance of approximately 7.5%-9.5% on a reported basis and approximately 7%-9% on an organic basis . The company earned an adjusted EPS of … Full story available on

Boston Scientific Q1 Earnings and Revenues Top Estimates
Apr 24, 2024 16:04pm

Boston Scientific (NYSE: BSX ) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.47 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 9.80%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $0.51 per share when it actually produced earnings of $0.55, delivering a surprise of 7.84%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Boston Scientific, which belongs to the Zacks Medical - Products industry, posted revenues of $3.86 billion for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 4.85%. This compares to year-ago revenues of $3.39 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock''s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management''s commentary on the earnings call.

Boston Scientific hits 52-week high on Q1 beat
Apr 24, 2024 15:53pm

No summary available.

Source:Seeking Alpha
Boston Scientific Beats Forecasts, Boosts Outlook on Booming Heart Device Sales
Apr 24, 2024 15:33pm

Boston Scientific exceeded profit and sales forecasts on demand for its cardiovascular devices.

Here’s Why Boston Scientific Corporation (BSX) Rose in Q1
Apr 24, 2024 15:16pm

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]

Source:Insider Monkey
Boston Scientific Pops Into Buy Zones On Solid First-Quarter Report
Apr 24, 2024 11:11am

Boston Scientific heads for two different buy zones after topping Q1 views and hoisting guidance above expectations.

Source:Investor''s Business Daily
Boston Scientific’s stock jumps 2.7% after earnings top estimates
Apr 24, 2024 10:38am

No summary available.

Boston Scientific Non-GAAP EPS of $0.56 beats by $0.05, revenue of $3.86B beats by $180M
Apr 24, 2024 10:32am

No summary available.

Source:Seeking Alpha
Boston Scientific Q1 2024 Earnings Preview
Apr 23, 2024 18:06pm

Boston Scientific is set to announce Q1 earnings on April 24th, with consensus estimates of $0.51 EPS and $3.68B revenue.

Source:Seeking Alpha
Boston Scientific Class I Recall Linked to Two Deaths
Apr 18, 2024 16:37pm

Categorized as a correction, not product removal, the company is recommending physicians not use the aliquot technique to deliver the Obsidio Conformable Embolic due to increased patient risk.